Platinum agents are drugs used for various types of cancer. With increased frequency of administration of platinum agents, hypersensitivity reactions appear more frequently, occurring in over 25% of cases from the seventh cycle or second line onward. It then becomes difficult to conduct treatment using these agents. Various approaches have been investigated to address hypersensitivity reactions to platinum agents. Desensitization, which gradually increases the concentration of the anticancer drug considered to be the antigen until the target dosage, has been reported as being particularly effective, with a success rate of 80-100%. The aims of this paper are to present the current findings regarding hypersensitivity reactions to platinum agents and to discuss attempts of using desensitization against hypersensitivity reactions worldwide.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jjco/hyv081 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spectroscopic, docking, antiproliferative, and anticancer activity of novel metal derivatives of phenylacetohydrazide Schiff base on different human cancer cell lines.
BMC Chem
March 2025
Chemistry Department, Faculty of Science, El-Fayoum University, El-Fayoum, Egypt.
In the last two decades, many Schiff bases have been investigated due to the importance of their metal complexes in the medical field and drug industry. The Schiff base metal complexes have several applications as anticancer agents because they have a high binding ability to nucleic acids (DNA and RNA). The Schiff base HL, derived from the condensation of 2-phenylacetohydrazide and 2-hydroxynaphthaldehyde, was reacted with Fe, Zn, Cd, and Pt to form the unique metal complexes [Fe(HL)], [Zn(HL)](CHCOO), [Cd(HL)](CHCOO), and [Pt(HL)Cl].
View Article and Find Full Text PDFSex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab.
Sci Rep
March 2025
Oncology Unit, Macerata Hospital, Via Santa Lucia 2, 62100, Macerata, Italy.
Gender- and sex-based disparities in response to immune-checkpoint inhibitors (ICI) has been reported in a variety of tumor types. Women have different anatomy with recurrent urinary tract infections, a different sex hormonal profile, and intrinsic differences in local and systemic immune systems and urobiome composition. Existing literature data in a pan-cancer context reveal contradictory results, and real-world evidence in urothelial carcinoma (UC) is lacking.
View Article and Find Full Text PDFA Facile Way to Enhance the Therapeutic Efficacy of Hydrophobic Drugs via Amorphous Solid Dispersions.
AAPS J
March 2025
School of Pharmacy, Changzhou University, Changzhou, 213164, P. R. China.
Approximately 40% of marketed drugs and 75% of invested drugs in the pharmaceutical field are poorly soluble hydrophobic drugs with minimal solubility in water which make them difficult to be absorbed by the body and significantly limiting their applications. Among chemotherapeutic agents, numerous antitumor drugs such as platinum compounds, camptothecin, paclitaxel and others are also restricted in processing and preparation due to solubility issues. Therefore, improving the solubility and enhancing the therapeutic efficacy of drugs have always been significant research topics in current pharmaceutics.
View Article and Find Full Text PDFBioeliminable Pt@BiSe-RGD Nanoassembly for Enhancing Photoacoustic Imaging-Guided Tumor Immuno-Radiotherapy by Inducing Apoptosis via the Areg Pathway.
Theranostics
March 2025
State Key Laboratory of Trauma and Chemical Poisoning, Institute of Combined Injury, Chongqing Engineering Research Center for Nanomedicine, College of Preventive Medicine, Army Medical University, Chongqing 400038, China.
Nanoradiosensitizers containing high Z-group elements have been reported widely as potential candidates for radiotherapy. However, the specific regulatory mechanism is unclear, and biodegradability needs to be addressed urgently. We synthesized a silk sericin-containing nano assembly, Pt@BiSe-RGD (PBR).
View Article and Find Full Text PDFTargeting platinum-resistant ovarian cancer by disrupting histone and RAD51 lactylation.
Theranostics
March 2025
Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, PR China.
Ovarian cancer is a highly lethal gynecological malignancy with common platinum resistance. Lactylation is involved in multiple biological processes. Thus, we explored the role of histone and non-histone lactylation in platinum resistance, providing a potential therapeutic target to overcome platinum resistance in ovarian cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!